Epigenetic Modulation and Bone Metastasis: Evolving Therapeutic Strategies
Pharmaceuticals · 31.07.2025 · 18 (8) · 1140
DOI: 10.3390/ph18081140 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 31.07.2025. Verfasst von Mahmoud Zhra und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Genetics, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 268 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bone metastasis remains a significant cause of morbidity and diminished quality of life in patients with advanced breast, prostate, and lung cancers. Emerging research highlights the pivotal role of reversible epigenetic alterations, including DNA methylation, histone modifications, chromatin remodeling complex dysregulation, and non-coding RNA networks, in orchestrating each phase of skeletal colonization. Site-specific promoter hypermethylation of tumor suppressor genes such as HIN-1 and RASSF1A, alongside global DNA hypomethylation that activates metastasis-associated genes, contributes to cancer cell plasticity and facilitates epithelial-to-mesenchymal transition (EMT). Key histone modifiers, including KLF5, EZH2, and the demethylases KDM4/6, regulate osteoclastogenic signaling pathways and the transition between metastatic dormancy and reactivation. Simultaneously, SWI/SNF chromatin remodelers such as BRG1 and BRM reconfigure enhancer–promoter interactions that promote bone tropism. Non-coding RNAs, including miRNAs, lncRNAs, and circRNAs (e.g., miR-34a, NORAD, circIKBKB), circulate via exosomes to modulate the RANKL/OPG axis, thereby conditioning the bone microenvironment and fostering the formation of a pre-metastatic niche. These mechanistic insights have accelerated the development of epigenetic therapies. DNA methyltransferase inhibitors (e.g., decitabine, guadecitabine) have shown promise in attenuating osteoclast differentiation, while histone deacetylase inhibitors display context-dependent effects on tumor progression and bone remodeling. Inhibitors targeting EZH2, BET proteins, and KDM1A are now advancing through early-phase clinical trials, often in combination with bisphosphonates or immune checkpoint inhibitors. Moreover, novel approaches such as CRISPR/dCas9-based epigenome editing and RNA-targeted therapies offer locus-specific reprogramming potential. Together, these advances position epigenetic modulation as a promising axis in precision oncology aimed at interrupting the pathological crosstalk between tumor cells and the bone microenvironment. This review synthesizes current mechanistic understanding, evaluates the therapeutic landscape, and outlines the translational challenges ahead in leveraging epigenetic science to prevent and treat bone metastases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anatomy and Genetics, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
- Department of Biochemistry and Molecular Medicine, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
ORCID-Profile: Mahmoud Zhra, Jasmine Hanafy Holail, Khalid S Mohammad
Zitieren
APA
Zhra, M., Holail, J. H., & Mohammad, K. S. (2025). Epigenetic Modulation and Bone Metastasis: Evolving Therapeutic Strategies. Pharmaceuticals, 18(8), 1140. https://doi.org/10.3390/ph18081140
Vancouver
Zhra M, Holail JH, Mohammad KS. Epigenetic Modulation and Bone Metastasis: Evolving Therapeutic Strategies. Pharmaceuticals. 2025;18(8):1140. doi:10.3390/ph18081140
BibTeX
@article{Zhra2025,
author = {Zhra, Mahmoud and Holail, Jasmine Hanafy and Mohammad, Khalid S},
title = {Epigenetic Modulation and Bone Metastasis: Evolving Therapeutic Strategies},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {8},
pages = {1140},
doi = {10.3390/ph18081140}
}
EUVIMED